Dejan Knezevic
PhD - Sr. Director, Biopharma Partnerships Natera
Dejan Knezevic, PhD, currently manages biopharma partnerships at Natera. Before joining Natera, Dejan completed his postdoctoral fellowship at Genentech & Roche Pharmaceuticals. He most recently served as the Senior Director of Business Development at Guardant Health. He received his PhD in Genetics/Physiology from Yale University.
Seminars
Natera has recently integrated Foresight’s phased-variant technology into the Signatera™ platform, combining ultrasensitive detection below 0.1 ppm with Natera’s market-leading commercial and operational infrastructure for MRD testing. This enhanced version of Signatera™ is offered alongside CLARITY™ and Latitude™, supporting tumor-informed and tissue-free MRD applications.
This Engager session will explore how incorporating additional variant classes enables the next level of ultrasensitivity and creates new opportunities for MRD-guided clinical trials.
- Earlier Intervention in High Risk Populations: With >250,000 patients tested in 2025, Natera has established access to a previously under-characterized but clinically meaningful population—enabling development in earlier disease settings where relapse risk is high and therapeutic impact may be greatest
- The Integration of Sensitivity and Scale: With the integration of Foresight’s phased-variant technology into the Signatera™ platform, Natera combines ultrasensitive detection capabilities below 0.1ppm with an expansive commercial and operational infrastructure to support MRD-guided studies at scale
- De-risking MRD-guided Development: Natera’s ecosystem of trial-enablement tools, including site selection support, real-world insights, and commercial-to-trial enrollment pathways, enables more efficient, lower-risk development
